Abstract
Purpose :
To evaluate the antiviral potential of five multipurpose disinfecting solutions against coronavirus (murine hepatitis virus a surrogate for SARS-CoV-2 human corona virus).
Methods :
Murine hepatitis virus ATCC/VR261 stock was prepared prior to testing by growing in A9 ATCC/CCL 1.4 cells in Dulbecco’s minimum essential medium (DMEM) containing 5% fetal bovine serum (FBS) and antibiotics (streptomycin sulphate and penicillin G). Test solutions (BioTrue, ReNu Advanced [Bausch and Lomb], ACUVUE RevitaLens [Johnson and Johnson Vision], cleadew [Ophtecs corp.] or AOSept Plus [Alcon]) were mixed with viruses at 104 plaque forming units (PFU)/mL as the final concentration and incubated at room temperature for the specified disinfection time as recommended by each manufacturer. Phosphate buffer saline (PBS) was used as a negative control. Surviving virus from each sample was then quantified by standard plaque forming unit assay and the reduction of PFU for each disinfectant was compared to the negative control.
Results :
The three multipurpose disinfecting solutions BioTrue (containing PHMB and polyquaternium-1), ReNu Advanced (PHMB, polyquaternium-1 and alexidine) and ACUVUE RevitaLens (polyquaternium-1 and alexidine) did not kill the coronavirus at the manufacturers recommended disinfection time. After treatment, the virus’s titer (3.8 ± 0.2 log10 for BioTrue, 3.7 ± 0.1 log10 for ReNu and 3.7 ± 0.2 log10 for Revitalens) was similar to the negative control (3.7 ± 0.1 log10). AOSept Plus (hydrogen peroxide) and cleadew (povidone iodine) reduced the numbers of coronaviruses to below the detection limit (i.e. killed 3.7 ± 0.1 log10 viruses compared to control).
Conclusions :
This study shows that oxidative contact lens disinfecting solutions (i.e. those containing povidone-iodine or hydrogen peroxide) provide superior antiviral activity against a coronavirus surrogate of SARS-CoV-2.
This is a 2021 ARVO Annual Meeting abstract.